Trial reportStroke2019
Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile.
Trial report in Stroke, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02604667 (Mechanisms of Ischemic Stroke in Cancer Patients), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanisms of Ischemic Stroke in Cancer Patients
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial.Journal of the American Heart Association · 2025Trial
- Genetic Insights Into Cryptogenic Stroke: From Etiologic Heterogeneity to Clinical Translation.Journal of stroke · 2026Review
- Molecular heterogeneity in human stroke - What can we learn from the peripheral blood transcriptome?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
- Identification of coagulation-related hub genes in ischemic stroke based on bioinformatics integration analysis and investigation of their immune regulatory mechanisms.European journal of medical research · 2025Article
- Cryptogenic embolic stroke and cancer.Frontiers in neurology · 2025Review
- Review
- Direct Oral Anticoagulants vs. Heparin for Cancer-Related Stroke: Augmented Meta-Analysis.medRxiv : the preprint server for health sciences · 2024Article
- Ischemic Stroke with Comorbid Cancer Has Specific miRNA-mRNA Networks in Blood That Vary by Ischemic Stroke Mechanism.Annals of neurology · 2024Article
- Malignancy-associated ischemic stroke: Implications for diagnostic and therapeutic workup.CNS neuroscience & therapeutics · 2024Review
- A case-control comparison of acute-phase peripheral blood gene expression in participants diagnosed with minor ischaemic stroke or stroke mimics.Human genomics · 2023Article
- Systematic analysis of brain and skull ischemic injury expression profiles reveals associations of the tumor immune microenvironment and cell death with ischemic stroke.Frontiers in immunology · 2022Article
- Role of Glial Cell-Derived Oxidative Stress in Blood-Brain Barrier Damage after Acute Ischemic Stroke.Oxidative medicine and cellular longevity · 2022Review
- Cancer and Embolic Stroke of Undetermined Source.Stroke · 2021Review
- High neutrophil/lymphocyte ratio at cancer diagnosis predicts incidence of stroke in cancer patients.Brain communications · 2021Article
- Stroke Exacerbates Cancer Progression by Upregulating LCN2 in PMN-MDSC.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
Abstract
Background and Purpose- Comorbid cancer is common in patients with acute ischemic stroke (AIS). As blood mRNA profiles can distinguish AIS mechanisms, we hypothesized that cancer-related AIS would have a distinctive gene expression profile. Methods- We evaluated 4 groups of 10 subjects prospectively enrolled at 3 centers from 2009 to 2018. This included the group of interest with active solid tumor cancer and AIS and 3 control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable). Subjects in the vascular risk factor group were matched to subjects in the cancer-stroke and stroke-only groups by age, sex, and vascular risk factors. Blood was drawn 72 to 120 hours after stroke. Total RNA was processed using 3' mRNA sequencing. ANOVA and Fisher least significant difference contrast methods were used to estimate differential gene expression between groups. Results- In the cancer-stroke group, 50% of strokes were cryptogenic. All groups had differentially expressed genes that could distinguish among them. Comparing the cancer-stroke group to the stroke-only group and after accounting for cancer-only genes, 438 genes were differentially expressed, including upregulation of multiple genes/pathways implicated in autophagy signaling, immunity/inflammation, and gene regulation, including IL (interleukin)-1, interferon, relaxin, mammalian target of rapamycin signaling, SQSTMI1 (sequestosome-1), and CREB1 (cAMP response element binding protein-1). Conclusions- This study provides evidence for a distinctive molecular signature in blood mRNA expression profiles of patients with cancer-related AIS. Future studies should evaluate whether blood mRNA can predict detection of occult cancer in patients with AIS. Clinical Trial Registration- URL: https://clinicaltrials.gov. Unique identifier: NCT02604667.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.